Daniel C. Martin
Net Worth
Last updated:
What is Daniel C. Martin net worth?
The estimated net worth of Mr. Daniel C. Martin is at least $5,748,228 as of 16 Feb 2024. He has earned $1,501,308 from insider trading and has received compensation worth at least $4,246,920 in Deciphera Pharmaceuticals, Inc..
What is the salary of Daniel C. Martin?
Mr. Daniel C. Martin salary is $707,820 per year as Senior Vice President & Chief Commercial Officer in Deciphera Pharmaceuticals, Inc..
How old is Daniel C. Martin?
Mr. Daniel C. Martin is 50 years old, born in 1975.
What stocks does Daniel C. Martin currently own?
As insider, Mr. Daniel C. Martin owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) | Senior Vice President & Chief Commercial Officer | 55,118 | $0 | $0 |
What does Deciphera Pharmaceuticals, Inc. do?
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Daniel C. Martin insider trading
Deciphera Pharmaceuticals, Inc.
Mr. Daniel C. Martin has made 12 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 2,267 units of DCPH stock worth $35,406 on 16 Feb 2024.
The largest trade he's ever made was exercising 26,999 units of DCPH stock on 22 Jan 2020. As of 16 Feb 2024 he still owns at least 55,118 units of DCPH stock.
Deciphera Pharmaceuticals key executives
Deciphera Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Daniel L. Flynn Ph.D. (70) Executive Vice President, Chief Scientific Officer & Founder
- Dr. Matthew L. Sherman (69) Executive Vice President & Chief Medical Officer
- Dr. Stephen B. Ruddy Ph.D. (61) Senior Vice President & Chief Technical Officer
- Mr. Daniel C. Martin (50) Senior Vice President & Chief Commercial Officer
- Mr. Steven L. Hoerter (54) Pres, Chief Executive Officer & Director
- Mr. Thomas Patrick Kelly J.D. (54) Executive Vice President, Chief Financial Officer & Treasurer